Singapore markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
206.20+1.98 (+0.97%)
At close: 04:00PM EDT
200.00 -6.20 (-3.01%)
After hours: 07:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close204.22
Open205.26
Bid206.09 x 1100
Ask206.05 x 900
Day's range203.13 - 207.36
52-week range187.16 - 468.55
Volume1,012,694
Avg. volume1,080,830
Market cap30.198B
Beta (5Y monthly)0.42
PE ratio (TTM)21.10
EPS (TTM)9.77
Earnings date20 Jul 2022 - 25 Jul 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est241.96
  • Zacks

    INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

    The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

  • Zacks

    How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

    Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

  • Motley Fool

    Is This Growth Stock Defeated After Collapsing 22% in a Year?

    With its shares down by more than 22% in the last 12 months, it's clear that Biogen (NASDAQ: BIIB) isn't the high-flying growth stock that it used to be. Since its failed attempt over the last year to get its fiercely criticized Alzheimer's disease drug Aduhelm approved for sale, the company's troubles have turned from bad to worse. Revenue and earnings from its core drug products are both down sharply over the last three years.